I guess my perspective on the question was in the immediate time should India need more than we can handle. Making monoclonal antibodies isn't popping a pill out of a machine. It literally took a year to migrate the manufacturing IP info from AGC to Samsung. Regulatory bodies then need to verify all processes are met to standards so we have quality leronlimab being created. It takes time it's not something that can just be pawned off on a whim because Samsung can't handle it. That's my point. If that is not what was being asked then I misinterpreted.